Mizuho Securities cut the price target to $8 from $17, BTIG to $6 from $10, and Wedbush to $7 from $9.
Magenta on Thursday said it will decrease its workforce by 14% and trim other costs as it works to develop its MGTA-117 drug candidate as a potential treatment for acute myeloid leukemia and myelodysplasia.
Price: 2.03, Change: -0.21, Percent Change: -9.60
|AvidXchange Says Its Invoice Payment Software Integr...|
|-- Earnings Flash (BACK) IMAC HOLDINGS Posts Q2 Reve...|
|Insider Sell: Franklin Resources|
|MPLX to Redeem 2022, 2023 Senior Notes|
|Amarin to Present Additional Data From Cardiovascula...|